Table 1

From the following article

Moving targets: cell migration inhibitors as new anti-inflammatory therapies

Charles R Mackay

Nature Immunology 9, 988 - 998 (2008) Published online: 19 August 2008

doi:10.1038/ni.f.210

BACK TO ARTICLE

Table 1. Promising targets and drug development programs for cell migration inhibitors

Figures and tables index
Disease indicationTarget moleculesDrugs in developmentCompanies

Table does not itemize all compounds, from every company, that are in development, nor reference every compound. Please refer to company websites for more information. Certain programs in preclinical development or phase 1 trials have been listed under selected indications, on the basis of theoretical considerations and not necessarily company disclosures. For further information on structures and other compounds in preclinical and clinical development, see ref. 89. PS, pan-selectin; SM, small molecule; mAb, monoclonal antibody.

Rheumatoid arthritisCCR5Maraviroc (SM)Pfizer
 CCR5SMSchering-Plough, phase 3
 CCR1SMChemoCentryx, phase 1
 C5aRAnti-C5aR mAbNovoNordisk/G2 Therapies, preclinical
 C5aRSMArana Therapeutics
 CXCR2SMSchering-Plough, phase 2
 CCR2INCB3284 (SM)Incyte, phase 2
Crohn's disease, ulcerative colitisCCR9CCX282 (SM)ChemoCentryx/GlaxoSmithKline, phase 3
 alpha4beta1 integrinNatalizumab (mAb)Biogen-Idec, approved
 alpha4beta7 integrinMLN002 (mAb)Millennium, phase 2
 CXCL10MDX-1100 (mAb)Medarex, phase 2
Multiple sclerosisalpha4beta1 integrinNatalizumab (mAb)Biogen-Idec, approved
 alpha4beta1 integrinSMTanabe, phase 2
 S1P receptorsFTY-720Novartis, phase 3
 S1P receptorsS1P1 (SM)Amgen/Predix, phase 1
 CCR2MK0812 (SM)Merck, phase 2
 CCR2SMChemoCentryx, phase 1
 CCR6SMChemoCentryx, preclinical
 CCR6mAbG2 Therapies, preclinical
PsoriasisLFA-1 (CD11a)EfalizumabGenentech, approved
 SelectinsBimosiamose (PS SM)Revotar, phase 2
 CCR4Depleting mAbAmgen/Kyowa-Hakko, phase 2
 CXCR2SMGlaxoSmithKline, preclinical
SLECXCR3SMAmgen, phase 1 completed
 C5aRSMChemoCentryx, preclinical
AsthmaCRTh2SMOxagen, phase 2
 CRTh2SMMillennium/Aventis, phase 1
 CCR3Bimosiamose (PS SM)Various, undisclosed
 Selectins Revotar, phase 2
Transplant rejectionCXCR2/CXCR1Reparixin (SM)Dompé pha.r.ma, phase 2
 CXCR3SM and mAbsVarious, undisclosed
 S1P receptorsFTY-720Novartis, phase 2
AtherosclerosisCCR2MLN002 (mAb)Millennium, phase 2
COPDCXCR2SCH 527123 (SM)Schering-Plough, phase 2
 SelectinsBimosiamose (PS SM)Revotar, phase 2
Age-related macular degenerationC5aRSMArana Therapeutics
 C5aRSMChemoCentryx, preclinical
 C5aRmAbNovoNordisk
Stem cell mobilizationCXCR4AMD3100 (SM)Genzyme, approved
Cancer metastasisCXCR4Modified CXCL12Chemokine Therapeutics, phase 1/2
 CXCR7SMChemoCentryx, preclinical
 CXCR7mAbmAb Design, preclinical
Figures and tables index
BACK TO ARTICLE